An Emerging Leader in Cancer Diagnostics
Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering diagnostic products and services that enable precision medicine in the field of oncology.
Products and services being developed at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI’s cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information where patients and their physicians need it most – to diagnose, monitor and inform cancer treatment.
CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our clinical reference laboratory is both CLIA-certified and CAP-accredited. In addition we have approvals and accreditations from the states of California, Florida, Maryland, New York, Pennsylvania, and New Jersey. Our clinical trial support services and global facilities help biotech and biopharma companies deliver more personalized treatments to market.
CGI is focused on delivering products and services that drive the highest levels of patient value. To achieve this, we have developed a corporate culture that inspires innovation, respects knowledge and fosters leadership. Our dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new tests. CGI’s full-service cancer genetic practice and path to innovation with research makes for optimal patient care management.
With locations in the US, India, and China, we are helping to empower personalized cancer treatment around the globe.
Cancer Genetics, Inc. was founded by world-renowned cytogeneticist Dr. R.S.K. Chaganti. Today, CGI’s scientific advisory board includes key thought leaders in the areas of hematological malignancies, solid tumor cancers, pharmacogenomics, and clinical trials administration. Built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, the company continues to develop strong research collaborations with major cancer centers and academic institutions.
In 2013, CGI launched a joint-venture with Mayo Clinic, Oncospire Genomics. Working to meet areas of critical need in oncology, Oncospire Genomics seeks to improve cancer care by discovering and commercializing diagnostic tests that leverage NGS technology.
In 2014, CGI acquired Gentris, LLC (based in Raleigh, NC) and Bioserve Biotechnologis Pvt. Ltd. (based in Hyderabad, India.
Gentris | A CGI Company is a market leader in providing pharmacogenomics testing, genotyping, and biorepository services to the pharmaceutical and biotech industries. Gentris advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care. Gentris’ clinical trials services, as well as their international services and Shanghi, China operations, have been integrated into CGI’s Select One® clinical trials offering, allowing CGI to provide the most robust and personalized clinical trial services available to our biotech and pharma customers.
Based in Hyderabad, India, BioServe India (now Cancer Genetics India) was the first company to provide DNA synthesis, DNA sequencing, and related services in India. Cancer Genetics India brings Indian cientists, pharmaceutical companies, and research institutes a ‘Biomaterial to Data’ model that offers a full suite of molecular services and research tools to accelerate breakthroughs in genetics, drug discovery, biomarker research, and molecular diagnostics. CG-India’s customers include nearly every Indian Council of Medical Research (ICMR) and Council for Scientific and Industrial Research (CSIR) institute and several major pharmaceutical and biotechnology companies, as well as top industry and academic researchers.